Return to Publications
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Return to Publications  |  Return to CINJ Home
Rutgers Cancer Institute of New Jersey's Cancer Connection, January 2015
Donate NowThe latest news on research, treatment, prevention and education from the
state's only National Cancer Institute-designated Comprehensive Cancer Center
Vaccine Therapy for Prostate Cancer Patients with Rising PSA Examined



Aiming to increase treatment options for prostate cancer patients who have an early relapse, investigators from a multi-institutional cooperative group - including Rutgers Cancer Institute of New Jersey - have demonstrated that a vaccine therapy that stimulates the body's own immune defenses can be given safely and earlier in the course of prostate cancer progression. Cancer Institute Director Robert S. DiPaola, MD, is the lead author of the work, which appeared in the December online issue of European Urology.Learn more

Examining the Effects of 'Chemo Brain' in Breast Cancer Patients



In an effort led by medical oncologist Serena Wong, MD, Rutgers Cancer Institute of New Jersey is referring breast cancer patients to a clinical trial examining the side effects of chemotherapy and hormonal therapy on the brain. Referred to as "chemo brain," these changes can affect a patient's quality of life. The study, sponsored by the National Institutes of Health and conducted by the Kessler Foundation in cooperation with the Cancer Institute of New Jersey, will look at the side effects of these medicines on breast cancer patients by looking at changes that occur inside the brain.Learn more

Platinum Agent Combination Treatment for Triple-Negative Breast Cancer Well Tolerated in Phase II Clinical Trial


pink ribbon

Research from Rutgers Cancer Institute of New Jersey shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. The work, which also included genomic profiling to measure molecular correlates of response, was presented at the recent San Antonio Breast Cancer Symposium.Learn more

A Closer Look at Measuring Cancer Survival



When looking at cancer, measures of survival are a valuable tool to clinicians, researchers and public health officials. New Jersey State Cancer Registry Director and Rutgers Cancer Institute of New Jersey resident member Antoinette Stroup, PhD, further examines this topic comparing relative survival rates that use state life tables to traditional methods that use U.S.-based life tables.Learn more

            Rutgers Cancer Institute of New Jersey                                          NCI logo 

Office of Communications         ·        ·        732-235-9871

                        Like us on Facebook                     Join the CINJ Mailing List